Public, NASDAQ:ONCY
NASDAQ Capital Market
Oncolytics Biotech Slumps In Pre-Market On Public Offering
Date: Fri, 28 Nov 2008 14:31:48 GMT
Tags:
Oncolytics Biotech Slumps In Pre-Market On Public Offering
Trading Markets (press release) - Nov 28, 2008
Trading Markets (press release) - Nov 28, 2008
(RTTNews) - Oncolytics Biotech (ONCY | Quote | Chart | News | PowerRating) dipped in pre-market trading, after unveiling a public offering of up to 2.5 million units at $1.50 per unit for gross ...
Oncolytics Biotech announces $3.75 mln equity offering - quick facts
Date: Thu, 27 Nov 2008 13:12:05 GMT
Tags:
Oncolytics Biotech announces $3.75 mln equity offering - quick facts
RTT News - Nov 27, 2008
RTT News - Nov 27, 2008
(RTTNews) - Oncolytics Biotech Inc. (ONC.TO: News ) (ONCY) announced entering into an engagement agreement with Bolder Investment Partners, Inc. in connection with a proposed equity financing. The ...
BRIEF-Oncolytics Biotech announces public offering
Date: Thu, 27 Nov 2008 12:51:33 GMT
Tags:
BRIEF-Oncolytics Biotech announces public offering
Interactive Investor - Nov 27, 2008
Interactive Investor - Nov 27, 2008
Interactive Investor Trading Limited, trading as "Interactive Investor", is authorised and regulated by the Financial Services Authority. Registered Office: Standon House, 21 Mansell Street ...
Oncolytics Biotech Inc. Announces Public Offering
Date: Thu, 27 Nov 2008 12:40:06 GMT
Tags:
Oncolytics Biotech Inc. Announces Public Offering
Canada NewsWire (press release) - Nov 27, 2008
Canada NewsWire (press release) - Nov 27, 2008
<< /NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF US SECURITIES LAW/ >> CALGARY ...
Common Virus Helps Quality Of Life For Sarcoma Patients Says Cancer Expert
Date: Thu, 20 Nov 2008 08:13:16 GMT
Tags:
Common Virus Helps Quality Of Life For Sarcoma Patients Says Cancer Expert
Medical News Today (press release) - Nov 20, 2008
Medical News Today (press release) - Nov 20, 2008
New data shows that some sarcoma patients are benefiting from treatment with REOLYSIN, developed from a harmless virus called the reovirus that most people are exposed to at some point in their ...
Common Virus Helps Quality of Life for Sarcoma Patients Says Cancer Expert - Newswise (press release)Oncolytics Biotech Inc. Announces Issuance of 30th U.S. Patent (PR Newswire)
Date: Tue, 18 Nov 2008 12:30:00 Etc/GMT
Tags:
Oncolytics Biotech Inc. today announced that it has been granted its 30th U.S. Patent, # 7,452,723, entitled "Methods for Preventing Reovirus Recognition for the Treatment of Cellular Proliferative Disorders."
Oncolytics Biotech Inc. Collaborators to Present REOLYSIN(R) Research at CTOS Annual Meeting (PR Newswire)
Date: Fri, 14 Nov 2008 12:30:00 Etc/GMT
Tags:
Oncolytics Biotech Inc. announced today that a poster presentation authored by Dr. Anders Kolb of the Nemours Center for Childhood Cancer Research entitled "Systemic Administration of REOLYSIN Inhibits Growth of Human Sarcoma Xenografts Alone and in Combination with Cisplatin and Radiation" is scheduled to be presented today at the 14th Annual Meeting of the Connective Tissue Oncology Society .
Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference (PR Newswire)
Date: Thu, 6 Nov 2008 21:25:00 Etc/GMT
Tags:
Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. , will present a corporate overview of the Company at the Rodman & Renshaw 10th Annual Healthcare Conference on Tuesday, November 11, 2008 at 11:10 a.m.
Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data (PR Newswire)
Date: Thu, 6 Nov 2008 17:00:00 Etc/GMT
Tags:
Oncolytics Biotech Inc. announced today that an oral presentation covering the interim results of a U.S. Phase II trial investigating intravenous REOLYSIN® in patients with bone and soft tissue sarcomas metastatic to the lung is being delivered today by Dr.
Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call (PR Newswire)
Date: Wed, 5 Nov 2008 20:00:00 Etc/GMT
Tags:
Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. , will host a conference call and webcast on Thursday, November 6, 2008 at 11:00 a.m. MT to update investors on clinical trial results in its U.S.